Asensus Surgical Inc (AMEX:ASXC)

$ 0.3277 0.0037 (1.14%) Market Cap: 89.28 Mil Enterprise Value: 85.75 Mil PE Ratio: 0 PB Ratio: 6.55 GF Score: 38/100

Q1 2024 Asensus Surgical Inc Earnings Call Transcript
May 14, 2024

$0.2789 (+5.84%)

Earnings
Q4 2023 Asensus Surgical Inc Earnings Call Transcript
Mar 21, 2024

$0.28 (-2.78%)

Earnings
Asensus Surgical Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Asensus Surgical Inc Earnings Call Transcript
Nov 14, 2023

$0.235 (+11.90%)

Earnings
Q2 2023 Asensus Surgical Inc Earnings Call Transcript
Aug 10, 2023

$0.3282 (+0.21%)

Earnings
Q1 2023 Asensus Surgical Inc Earnings Call Transcript
May 11, 2023

$0.628 (-7.65%)

Earnings
Asensus Surgical Inc Investor Day Transcript
Feb 21, 2023
Asensus Surgical Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Asensus Surgical Inc Earnings Call Transcript
Nov 10, 2022

$0.4279 (+4.34%)

Earnings
Q2 2022 Asensus Surgical Inc Earnings Call Transcript
Aug 08, 2022

$0.56 (-0.36%)

Earnings
Q1 2022 Asensus Surgical Inc Earnings Call Transcript
May 04, 2022

$0.44

Earnings
Q4 2021 Asensus Surgical Inc Earnings Call Transcript
Feb 28, 2022

$0.77 (+1.33%)

Earnings
Asensus Surgical Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Q3 2021 Asensus Surgical Inc Earnings Call Transcript
Nov 03, 2021

$1.85

Earnings
Q2 2021 Asensus Surgical Inc Earnings Call Transcript
Aug 05, 2021

$2.36 (+2.16%)

Earnings
Asensus Surgical Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Q1 2021 Asensus Surgical Inc Earnings Call Transcript
May 11, 2021

$1.88 (+13.25%)

Earnings
Q4 2020 Asensus Surgical Inc Earnings Call Transcript
Mar 11, 2021

$4.2 (+9.09%)

Earnings
Transenterix Inc Corporate Analyst Meeting Transcript
Feb 23, 2021
Q3 2020 Transenterix Inc Earnings Call Transcript
Nov 05, 2020

$0.3984 (+8.17%)

Earnings
Q2 2020 Transenterix Inc Earnings Call Transcript
Aug 05, 2020

$0.4807 (-4.51%)

Earnings
Q1 2020 Transenterix Inc Earnings Call Transcript
May 14, 2020

$0.39 (-15.22%)

Earnings
Q4 2019 Transenterix Inc Earnings Call Transcript
Mar 16, 2020

$0.3601 (-6.44%)

Earnings
Transenterix Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
TransEnterix, Inc. - Special Call Transcript
Dec 06, 2019
Q3 2019 Transenterix Inc Earnings Call Transcript
Nov 12, 2019

$3.97 (+14.74%)

Earnings
Q2 2019 Transenterix Inc Earnings Call Transcript
Aug 07, 2019

$14.95 (-3.36%)

Earnings
Q1 2019 Transenterix Inc Earnings Call Transcript
May 09, 2019

$27.3 (+1.45%)

Earnings
Q4 2018 Transenterix Inc Earnings Call Transcript
Feb 26, 2019

$35.36 (-14.73%)

Earnings

TransEnterix, Inc. - Special Call Transcript

Dec 06, 2019 / 04:00PM GMT

Release Date Price: $2.33 (-4.90%)

Transcript

Anthony Fernando

TransEnterix, Inc. - President, CEO & Director

Good morning, and welcome to the Transenterix Surgeon Panel Discussion & New Technology Demonstration. I'm Anthony Fernando, TransEnterix' President and CEO.

As a reminder, today's event is being recorded and will be available at the Investor Relations section of our website.

During today's event, we may be making some forward-looking statements regarding our business, or statements about the development of our technology. I'll pause here for just a moment to allow you to review our forward-looking statements.

Let's get started.

Thanks again for joining us this morning. The focus of today's event is to provide insights into real-world application of Senhance and provide additional details around our technology pipeline as well as provide the opportunity to have both company and surgeon panel address specific questions.

We recognize that potential customers and investors have heard about the technology and the market directly from us multiple times, and we wanted to take this

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.